Journal Mobile Options
Table of Contents
Vol. 20, No. 6, 2005
Issue release date: November–December 2005
Fetal Diagn Ther 2005;20:485–493

Feasibility of Retroviral Vector-Mediated in utero Gene Transfer to the Fetal Rabbit

Moreno R. · Rosal M. · Cabero L. · Gratacós E. · Aran J.M.
aMedical and Molecular Genetics Center, Institut de Recerca Oncològica, Hospital Duran i Reynals, L’Hospitalet de Llobregat, bAnimal Care Facility, Research Building, Institut de Recerca Hospital Universitari Vall d’Hebron, and cFetal Medicine Unit, Obstetrics and Gynecology Department, Hospital Universitari Materno-Infantil Vall d’Hebron, Barcelona, Spain

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Objectives: Successful treatment or prevention of severe hereditary diseases could conceivably be achieved by genetic intervention early in development. Viral vector-mediated fetal gene transfer is proving a valuable tool to test the above concept in relevant animal models. Although the pregnant rabbit is a well-recognized model for fetal therapy, few preclinical assays have used it to validate fetal gene transfer approaches. In this preliminary study we assessed for the first time the feasibility of retroviral vector-mediated in utero gene transfer in the fetal rabbit. Methods: Different amounts of the vesicular stomatitis virus G pseudotyped MFG(nls)LacZ retroviral vector, expressing a nuclear-localized β-galactosidase reporter protein were injected intraperitoneally and -hepatically into 20- to 22-day-old fetuses. At 8–9 days post-treatment, the pups were sacrificed and the tissues harvested for analysis. Evidence of gene transfer was obtained by PCR amplification of proviral sequences within genomic DNA isolated from the treated samples. Transgenic β-galactosidase expression was assessed by X-gal histochemical staining. Results: By intraperitoneal injection 43% of the viable fetuses treated (3/7) showed evidence of successful LacZ gene transfer and low-level β-galactosidase expression into liver and heart, whereas by intrahepatic injection roughly 38% (3/8) of the livers were positive for LacZ gene transfer and expression. The success rate for the viable fetuses rose to 67% positive livers (4/6) when a near double amount of recombinant virus was injected using a 10-fold concentrated virus stock. In terms of short-term safety, fetal and maternal survival rates approached 80% of treated fetuses, and 100% of treated does. Conclusions: The pregnant rabbit is a useful and reliable model allowing the design of further studies to optimize the conditions for effective, safer, and persistent retroviral vector-mediated fetal gene transfer.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Chowdhury JR, Wolkoff AW, Chowdhury NR, Arias IM: Hereditary jaundice and disorders of bilirubin metabolism; in Scriver CR, Beaudet AL, Sly WS, Valle D (eds): The Metabolic and Molecular Bases of Inherited Disease. New York, McGraw-Hill, 2001, pp 3063–3101.
  2. Mitchell GA, Grompe M, Lambert M, Tanguay RM: Hypertyrosinemia; in Scriver CR, Beaudet AL, Sly WS, Valle D (eds): The Metabolic and Molecular Bases of Inherited Disease. New York, McGraw-Hill, 2001, pp 1777–1805.
  3. Valle D, Simell O: The Hyperornithinemias; in Scriver CR, Beaudet AL, Sly WS, Valle D (eds): The Metabolic and Molecular Bases of Inherited Disease. New York, McGraw-Hill, 2001, pp 1857–1895.
  4. Zanjani ED, Anderson WF: Prospects for in utero human gene therapy. Science 1999;285:2084–2088.
  5. David AL, Themis M, Cook T, Coutelle C, Rodeck CH: Fetal gene therapy. Ultrasound Rev Obstet Gynecol 2001;1:14–27.

    External Resources

  6. Senut MC, Gage FH: Prenatal gene therapy: can the technical hurdles be overcome? Mol Med Today 1999;5:152–156.
  7. Hacein-Bey-Abina S, von Kalle C, Schmidt M, Le Deist F, Wulffraat N, McIntyre E, Radford I, Villeval JL, Fraser CC, Cavazzana-Calvo M, Fischer A: A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 2003;348:255–256.
  8. Pannell D, Ellis J: Silencing of gene expression: implications for design of retrovirus vectors. Rev Med Virol 2001;11:205–217.
  9. Coutelle C, Themis M, Waddington S, Gregory L, Nivsarkar M, Buckley S, Cook T, Rodeck C, Peebles D, David A: The hopes and fears of in utero gene therapy for genetic disease – a review. Placenta 2003;24:S114–S121.

    External Resources

  10. Wang G, Williamson R, Mueller G, Thomas P, Davidson BL, McCray PB Jr: Ultrasound-guided gene transfer to hepatocytes in utero. Fetal Diagn Ther 1998;13:197–205.
  11. Baumgartner TL, Baumgartner BJ, Hudon L, Moise KJ Jr: Ultrasonographically guided direct gene transfer in utero: successful induction of beta-galactosidase in a rabbit model. Am J Obstet Gynecol 1999;181:848–852.
  12. Wu Y, Liu J, Woo S, Finegold MJ, Brandt ML: Prenatal orogastric gene delivery results in transduction of the small bowel in the fetal rabbit. Fetal Diagn Ther 1999;14:323–327.
  13. Boyle MP, Enke RA, Adams RJ, Guggino WB, Zeitlin PL: In utero AAV-mediated gene transfer to rabbit pulmonary epithelium. Mol Ther 2001;4:115–121.
  14. Burns JC, Friedmann T, Driever W, Burrascano M, Yee JK: Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells. Proc Natl Acad Sci USA 1993;90:8033–8037.
  15. Aran JM, Gottesman MM, Pastan I: Construction and characterization of bicistronic retroviral vectors encoding the multidrug transporter and beta-galactosidase or green fluorescent protein. Cancer Gene Ther 1998;5:195–206.
  16. Humeau L, Chabannon C, Firpo MT, Mannoni P, Bagnis C, Roncarolo MG, Namikawa R: Successful reconstitution of human hematopoiesis in the SCID-hu mouse by genetically modified, highly enriched progenitors isolated from fetal liver. Blood 1997;90:3496–3506.
  17. Senoo M, Matsubara Y, Fujii K, Nagasaki Y, Hiratsuka M, Kure S, Uehara S, Okamura K, Yajima A, Narisawa K: Adenovirus-mediated in utero gene transfer in mice and guinea pigs: tissue distribution of recombinant adenovirus determined by quantitative TaqMan-polymerase chain reaction assay. Mol Genet Metab 2000;69:269–276.
  18. Heikkila A, Hiltunen MO, Turunen MP, Keski-Nisula L, Turunen AM, Rasanen H, Rissanen TT, Kosma M, Manninen H, Heinonen S, Yla-Herttuala S: Angiographically guided utero-placental gene transfer in rabbits with adenoviruses, plasmid/liposomes and plasmid/polyethyleneimine complexes. Gene Ther 2001;8:784–788.
  19. Meertens L, Zhao Y, Rosic-Kablar S, Li L, Chan K, Dobson H, Gartley C, Lutzko C, Hopwood J, Kohn D, Kruth S, Hough MR, Dube ID: In utero injection of alpha-L-iduronidase-carrying retrovirus in canine mucopolysaccharidosis type I: infection of multiple tissues and neonatal gene expression. Hum Gene Ther 2002;13:1809–1820.
  20. Tarantal AF, O’Rourke JP, Case SS, Newbound GC, Li J, Lee CI, Baskin CR, Kohn DB, Bunnell BA: Rhesus monkey model for fetal gene transfer: studies with retroviral-based vector systems. Mol Ther 2001;3:128–138.
  21. Nelson JM, Krummel TM, Haynes JH, Flood LC, Sauer L, Flake AW, Harrison MR: Operative techniques in the fetal rabbit. J Invest Surg 1990;3:393–398.
  22. Buchmiller TL, Kim CS, Chopourian HL, Fonkalsrud EW: Transamniotic fetal feeding: enhancement of growth in a rabbit model of intrauterine growth retardation. Surgery 1994;116:36–41.
  23. Gratacos E, Yamamoto H, Papadopulos NA, Adriaenssens T, Phlips T, Lerut TE, Deprest JA: The midgestational rabbit as a model for the creation of membrane defects after needle fetoscopy. Am J Obstet Gynecol 1999;180:1263–1267.
  24. Pringle KC: Human fetal lung development and related animal models. Clin Obstet Gynecol 1986;29:502–513.
  25. Beaudoin S, Barbet P, Bargy F: Developmental stages in the rabbit embryo: guidelines to choose an appropriate experimental model. Fetal Diagn Ther 2003;18:422–427.
  26. Tran ND, Porada CD, Almeida-Porada G, Glimp HA, Anderson WF, Zanjani ED: Induction of stable prenatal tolerance to beta-galactosidase by in utero gene transfer into preimmune sheep fetuses. Blood 2001;97:3417–3423.
  27. Douar AM, Themis M, Sandig V, Friedmann T, Coutelle C: Effect of amniotic fluid on cationic lipid mediated transfection and retroviral infection. Gene Ther 1996;3:789–796.
  28. Pitt BR, Schwarz MA, Pilewski JM, Nakayama D, Mueller GM, Robbins PD, Watkins SA, Albertine KH, Bland RD: Retrovirus-mediated gene transfer in lungs of living fetal sheep. Gene Ther 1995;2:344–350.
  29. Douar AM, Adebakin S, Themis M, Pavirani A, Cook T, Coutelle C: Foetal gene delivery in mice by intra-amniotic administration of retroviral producer cells and adenovirus. Gene Ther 1997;4:883–890.
  30. Turkay A, Saunders T, Kurachi K: Intrauterine gene transfer: gestational stage-specific gene delivery in mice. Gene Ther 1999;6:1685–1694.
  31. Porada CD, Tran N, Eglitis M, Moen RC, Troutman L, Flake AW, Zhao Y, Anderson WF, Zanjani ED: In utero gene therapy: transfer and long-term expression of the bacterial neo(r) gene in sheep after direct injection of retroviral vectors into preimmune fetuses. Hum Gene Ther 1998;9:1571–1585.
  32. Tran ND, Porada CD, Zhao Y, Almeida-Porada G, Anderson WF, Zanjani ED: In utero transfer and expression of exogenous genes in sheep. Exp Hematol 2000;28:17–30.
  33. Chow YH, O’Brodovich H, Plumb J, Wen Y, Sohn KJ, Lu Z, Zhang F, Lukacs GL, Tanswell AK, Hui CC, Buchwald M, Hu J: Development of an epithelium-specific expression cassette with human DNA regulatory elements for transgene expression in lung airways. Proc Natl Acad Sci USA 1997;94:14695–14700.
  34. Ramezani A, Hawley TS, Hawley RG: Performance- and safety-enhanced lentiviral vectors containing the human interferon-beta scaffold attachment region and the chicken beta-globin insulator. Blood 2003;101:4717–4724.
  35. Aran JM, Gottesman MM, Pastan I: Drug-selected coexpression of human glucocerebrosidase and P-glycoprotein using a bicistronic vector. Proc Natl Acad Sci USA 1994;91:3176–3180.
  36. Aran JM, Licht T, Gottesman MM, Pastan I: Complete restoration of glucocerebrosidase deficiency in Gaucher fibroblasts using a bicistronic MDR retrovirus and a new selection strategy. Hum Gene Ther 1996;7:2165–2175.
  37. Tarantal AF, Lee CI, Ekert JE, McDonald R, Kohn DB, Plopper CG, Case SS, Bunnell BA: Lentiviral vector gene transfer into fetal rhesus monkeys (Macaca mulatta): lung-targeting approaches. Mol Ther 2001;4:614–621.
  38. MacKenzie TC, Kobinger GP, Kootstra NA, Radu A, Sena-Esteves M, Bouchard S, Wilson JM, Verma IM, Flake AW: Efficient transduction of liver and muscle after in utero injection of lentiviral vectors with different pseudotypes. Mol Ther 2002;6:349–358.
  39. Seppen J, van der Rijt R, Looije N, van Til NP, Lamers WH, Oude Elferink RP: Long-term correction of bilirubin UDP-glucuronyltransferase deficiency in rats by in utero lentiviral gene transfer. Mol Ther 2003;8:593–599.
  40. Waddington SN, Mitrophanous KA, Ellard FM, Buckley SM, Nivsarkar M, Lawrence L, Cook HT, Al-Allaf F, Bigger B, Kingsman SM, Coutelle C, Themis M: Long-term transgene expression by administration of a lentivirus-based vector to the fetal circulation of immuno-competent mice. Gene Ther 2003;10:1234–1240.
  41. Gregory LG, Waddington SN, Holder MV, Mitrophanous KA, Buckley SM, Mosley KL, Bigger BW, Ellard FM, Walmsley LE, Lawrence L, Al-Allaf F, Kingsman S, Coutelle C, Themis M: Highly efficient EIAV-mediated in utero gene transfer and expression in the major muscle groups affected by Duchenne muscular dystrophy. Gene Ther 2004; DOI:10.1038/
  42. MacSween RNM, Desmet VJ, Roskams T, Scothorne RJ: Developmental anatomy and normal structure; in MacSween RMN, Burt AD, Portmann BC, Ishak KG, Scheuer PJ, Anthony PP (eds): Pathology of the Liver. New York, Churchill Livingstone, 2002, pp 1–66.
  43. Ohkubo T, Bárcena A, Smith CA, Harrison MR, Muench MO: High-efficiency retroviral transduction of fetal liver CD38-CD34++ cells: implications for in utero and ex utero gene therapy. Fetal Diagn Ther 2001;16:299–307.
  44. Park F, Ohashi K, Kay MA: The effect of age on hepatic gene transfer with self-inactivating lentiviral vectors in vivo. Mol Ther 2003;8:314–323.
  45. Gratacos E, Deprest J: Current experience with fetoscopy and the Eurofoetus registry for fetoscopic procedures. Eur J Obstet Gynecol Reprod Biol 2000;92:151–159.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50